Primaquine Inhibits Ferroptosis via GSTA1 to Protect Retinal Neurons

Study Background and Research Question

Retinal ischemia/reperfusion (I/R) injury is a central contributor to vision loss in a range of ocular diseases, including glaucoma, central retinal artery occlusion, and diabetic retinopathy. The underlying pathology often involves the loss of retinal neurons through both necrosis and regulated cell death mechanisms. Ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, has recently emerged as a key player in neuronal damage following I/R injury. However, its precise regulation and the potential for pharmacological intervention remain incompletely understood. The study by Lu et al. (Biomedicine & Pharmacotherapy, 2026) addresses whether primaquine, a classic antimalarial agent, can inhibit ferroptosis in the context of retinal I/R injury, and if so, through what mechanism.

Key Innovation from the Reference Study

The principal innovation of this research lies in the identification of primaquine as a previously unrecognized inhibitor of ferroptosis. Using both in vivo (acute high intraocular pressure mouse model) and in vitro (oxygen-glucose deprivation/reoxygenation in R28 retinal cells) systems, the authors demonstrate that primaquine robustly protects retinal neurons from I/R-induced death. Mechanistically, the study employs transcriptomic analysis to reveal that glutathione S-transferase alpha 1 (GSTA1) is a key molecular target through which primaquine exerts its anti-ferroptotic effect. This link between a clinically approved drug, a well-characterized enzymatic pathway, and ferroptosis represents a substantial advance in the field of neuroprotection.

Methods and Experimental Design Insights

The authors used an integrated approach combining animal models and cell culture systems to dissect the effects of primaquine on ferroptosis in retinal neurons. In the animal model, retinal I/R injury was induced by acute elevation of intraocular pressure, recapitulating key features of human disease. In vitro, R28 retinal cells were subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) to model ischemic stress, as well as treated with classical ferroptosis inducers Erastin and RSL3. Transcriptomic sequencing was performed at both tissue and cellular levels to pinpoint gene expression changes linked to primaquine treatment.

To probe the mechanistic underpinnings, the study measured markers of ferroptosis, including reactive oxygen species (ROS) accumulation, ferrous iron (Fe2+) levels, and the expression of the cystine/glutamate antiporter SLC7A11 and glutathione peroxidase 4 (GPX4), both established modulators of ferroptosis. GSTA1’s role was tested by genetic knockdown experiments, assessing whether loss of GSTA1 reverses primaquine-mediated neuroprotection.

Protocol Parameters

• Animal model of I/R injury: Acute high intraocular pressure (aHIOP) in mice to induce retinal ischemia followed by reperfusion.
• Cellular model: R28 retinal cells exposed to oxygen-glucose deprivation/reoxygenation (OGD/R) as an in vitro ischemia model.
• Primaquine treatment: Administered both in vivo and in vitro; precise dosing and timing detailed in the original study.
• Ferroptosis induction: Use of Erastin and RSL3 to pharmacologically induce ferroptosis in cell culture.
• Assessment endpoints: Retinal ganglion cell (RGC) survival, retinal thickness, ROS and Fe2+ quantification, mitochondrial morphology, and protein expression (SLC7A11, GPX4, GSTA1).
• GSTA1 knockdown: Genetic silencing in R28 cells to dissect the dependency of primaquine’s effect on GSTA1 activity.

Core Findings and Why They Matter

The study demonstrates several important outcomes. Primaquine treatment significantly reduced cell death in both animal and cell-based models of retinal I/R injury. This protection extended to cases where ferroptosis was specifically induced by Erastin or RSL3. Notably, primaquine suppressed ROS and Fe2+ accumulation, improved mitochondrial ultrastructure, and upregulated SLC7A11 and GPX4 levels—hallmarks of ferroptosis inhibition. Crucially, the upregulation of GSTA1 was identified as essential: knockdown of GSTA1 abolished the protective effects of primaquine, confirming its centrality in the observed neuroprotection (Lu et al., 2026).

These results suggest that targeting GSTA1 or related pathways could be a promising strategy for mitigating neuron loss in retinal I/R injury, a major cause of vision impairment. The demonstration that a clinically approved drug can modulate ferroptosis through a defined enzymatic pathway also opens new avenues for drug repurposing in neurodegenerative and ocular disease contexts.

Comparison with Existing Internal Articles

While the current study focuses on neuronal survival and ferroptosis inhibition, a related technical challenge in such mechanistic research is the accurate detection of low-abundance proteins involved in cell death pathways. Internal resources such as "ECL Chemiluminescent Substrate Detection Kit: Enabling Detection of Low-Abundance Proteins" and "Unveiling Protein Detection Limits: ECL Chemiluminescent Substrate Detection Kit (Hypersensitive)" (see internal article) highlight the importance of highly sensitive immunoblotting approaches for quantifying regulatory proteins like GPX4, SLC7A11, or GSTA1 in retinal tissue or cultured cells. These articles emphasize how hypersensitive ECL chemiluminescent substrates, particularly those optimized for horseradish peroxidase (HRP) chemiluminescence, enable robust detection of proteins in the low picogram range—critical for mechanistic studies of cell death and survival.

Furthermore, "Translational Protein Detection: Hypersensitive ECL in Action" (internal article) contextualizes the use of advanced chemiluminescent detection kits in translational research, especially for low-abundance biomarkers implicated in neurodegeneration. This complements the present study by underscoring the technical requirements for reliable protein quantification in ferroptosis research.

Limitations and Transferability

Despite the rigorous experimental design, several limitations should be considered. First, while the study provides compelling preclinical evidence in mouse and cell models, the translation of primaquine’s neuroprotective effects to human retinal diseases remains to be established. The dosing regimens and pharmacokinetics of primaquine in ocular tissues also require further optimization for clinical relevance. Additionally, although GSTA1 is shown to be necessary for primaquine’s anti-ferroptotic activity, the broader landscape of potential off-target effects or interactions with other ferroptosis pathways warrants further investigation.

Transferability to other forms of regulated cell death or to non-retinal tissues is not addressed; thus, the findings should be interpreted within the context of retinal I/R injury and experimental ferroptosis models.

Research Support Resources

Researchers aiming to replicate or extend these findings may require ultrasensitive detection of regulatory proteins such as GSTA1, SLC7A11, and GPX4 in retinal tissues or cell cultures. The ECL Chemiluminescent Substrate Detection Kit (Hypersensitive) (SKU K1231) offers highly sensitive HRP-mediated chemiluminescent detection suitable for immunoblotting of low-abundance proteins on nitrocellulose or PVDF membranes. According to product information, this kit supports low picogram sensitivity and extended signal duration, making it a practical choice for studies where detection reliability and sensitivity are critical. For additional technical context, see the internal discussion in "ECL Chemiluminescent Substrate Detection Kit: Enabling Detection of Low-Abundance Proteins."